SCHEMBL17951906

SCHEMBL17951906

C=NC1CN(c2cnc3[nH]cc(-c4ccccc4)c3c2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 5/20 0.53
▸ CDK8 P49336 1/20 0.53
▸ TNIK Q9UKE5 1/20 0.53
▸ JAK2 O60674 2/20 0.51
▸ PLK4 O00444 2/20 0.51
▸ AURKA O14965 2/20 0.51
▸ ROCK2 O75116 2/20 0.51
▸ PRKD3 O94806 2/20 0.51
▸ INSR P06213 2/20 0.51
▸ CDK1 P06493 2/20 0.51
▸ FES P07332 2/20 0.51
▸ ROS1 P08922 2/20 0.51
▸ FGFR1 P11362 2/20 0.51
▸ PHKG2 P15735 2/20 0.51
▸ FER P16591 2/20 0.51
▸ FLT1 P17948 2/20 0.51
▸ CDK2 P24941 2/20 0.51
▸ MARK3 P27448 2/20 0.51
▸ FLT4 P35916 2/20 0.51
▸ KDR P35968 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17951905 0.90 NTRK1 (0.48) AXLCDK8TNIKNTRK1MAPK1
SCHEMBL19351251 0.80 AXL (0.61) AXLCDK8TNIKJAK2PLK4
SCHEMBL19068211 0.79 AXL (0.59) AXLCDK8TNIKJAK2PLK4
SCHEMBL17952137 0.78 AXL (0.52) AXLCDK8TNIKJAK2PLK4
SCHEMBL17939184 0.78 JAK2 (0.48) AXLCDK8TNIKJAK2PLK4
SCHEMBL17939194 0.77 AXL (0.48) AXLCDK8TNIKJAK2PLK4
SCHEMBL17938957 0.75 SGK1 (0.48) AXLCDK8TNIKJAK2PLK4
SCHEMBL17939436 0.73 JAK3 (0.51) AXLCDK8TNIKJAK2JAK3
SCHEMBL17939379 0.73 JAK3 (0.51) AXLCDK8TNIKJAK2JAK3
SCHEMBL17939377 0.73 JAK3 (0.51) AXLCDK8TNIKJAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016118951-A2 HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER CONFLUENCE LIFE SCIENCES, INC. (US) 2016-07-28 — — WO disclosed
Send feedback